SCHEMBL6921497

SCHEMBL6921497

CC(c1nc2cc(-c3ccccn3)ccc2c(=O)n1C)N(C)C1CCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.42
TGFBR1 P36897 1/20 0.36
PKM P14618 2/20 0.35
CACNA2D1 P54289 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
MITF O75030 1/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SYK P43405 2/20 0.34
METAP2 P50579 1/20 0.34
FLT3 P36888 1/20 0.34
AURKB Q96GD4 1/20 0.34
DHODH Q02127 1/20 0.34
CTSD P07339 1/20 0.34
NR1D1 P20393 1/20 0.34
KCNH2 Q12809 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
BRD4 O60885 1/20 0.33
NPY5R Q15761 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059503 0.87 CYP3A4 (0.46) CYP3A4TGFBR1CACNA2D1GSK3BDYRK1A
SCHEMBL12059125 0.85 CYP3A4 (0.45) CYP3A4TGFBR1CACNA2D1METAP2DHODH
SCHEMBL2050982 0.81 POLB (0.46) CACNA2D1NPC1RAB9AATMRXFP1
SCHEMBL6921132 0.79 CYP3A4 (0.46) CYP3A4TGFBR1CACNA2D1SYKMETAP2
SCHEMBL6920827 0.79 CYP3A4 (0.48) CYP3A4TGFBR1METAP2DHODHNR1D1
SCHEMBL6922265 0.76 CYP3A4 (0.46) CYP3A4TGFBR1CACNA2D1SYKMETAP2
SCHEMBL6921561 0.73 CYP3A4 (0.46) CYP3A4TGFBR1CACNA2D1GSK3BDYRK1A
SCHEMBL12059505 0.73 CYP3A4 (0.47) CYP3A4TGFBR1GSK3BDYRK1AMETAP2
SCHEMBL6920558 0.73 CYP3A4 (0.45) CYP3A4TGFBR1GSK3BDYRK1AALDH1A1
SCHEMBL6922232 0.73 CYP3A4 (0.45) CYP3A4TGFBR1GSK3BDYRK1AMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 CYP3A4 4447/4885TGFBR1 3543/4885PKM 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.